drugset / Trial / NCT07684833

Randomized, Placebo-crontrolled Clinical Trial Evaluating the Efficacy and Safety of Heparan Sulfate 120 mg Prolonged-Release Tablets Compared With Placebo in Patients With Chronic Venous Disease

NCT07684833 ↗

Phase 3 Not yet recruiting 174 enrolled Farmaceutici Damor Spa
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This multicenter, randomized, double-blind study is a phase III evaluates the safety and effectiveness of CLR prolonged-release tablets in patients with chronic venous insufficiency, has been shown to be effective in reducing the symptoms of itching, edema, spontaneous pain, and night cramps chronic venous disease.

Timeline

Start
2026-11
Primary completion
2027-05
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Heparan Sulphate Unknown 120 mg Oral